IMMUNOGENICITY OF DNA VACCINE CONSTRUCTS ENCODING INFLUENZA VIRUS ARTIFICIAL ANTIGENS
- Authors: Starostina E.V.1, Kaplina O.N.1, Karpenko L.I.1, Dudko S.G.1, Bazhan S.I.1
-
Affiliations:
- State Research Center of Virology and Biotechnology «Vector» Rospotrebnadzor
- Issue: Vol 22, No 2-2 (2019)
- Pages: 1024-1026
- Section: ORIGINAL ARTICLES
- URL: https://journals.rcsi.science/1028-7221/article/view/120250
- DOI: https://doi.org/10.31857/S102872210006484-7
- ID: 120250
Cite item
Full Text
Abstract
About the authors
E. V. Starostina
State Research Center of Virology and Biotechnology «Vector» Rospotrebnadzor
Author for correspondence.
Email: starostina_ev@vector.nsc.ru
researcher of Bioengineering Department,
Koltsovo, Novosibirsk region
Russian FederationO. N. Kaplina
State Research Center of Virology and Biotechnology «Vector» Rospotrebnadzor
Email: fake@neicon.ru
researcher of Bioengineering Department,
Koltsovo, Novosibirsk region
Russian FederationL. I. Karpenko
State Research Center of Virology and Biotechnology «Vector» Rospotrebnadzor
Email: fake@neicon.ru
PhD, Dr. Sci., head of Recombinant vaccines Laboratory of Bioengineering Department,
Koltsovo, Novosibirsk region
Russian FederationS. G. Dudko
State Research Center of Virology and Biotechnology «Vector» Rospotrebnadzor
Email: fake@neicon.ru
researcher of Bioengineering Department,
Koltsovo, Novosibirsk region
Russian FederationS. I. Bazhan
State Research Center of Virology and Biotechnology «Vector» Rospotrebnadzor
Email: fake@neicon.ru
PhD, Dr. Sci., head of Theoretical Department,
Koltsovo, Novosibirsk region
Russian FederationReferences
- Wacheck V., Egorov A., Groiss F., Pfeiff er A., Fuereder T., Hoefl mayer D., Kundi M., Popow-Kraupp T., Redlberger-Fritz M., Mueller C.A., Cinatl J., Michaelis M., Geiler J., Bergmann M., Romanova J., Roethl E., Morokutti A., Wolschek M., Ferko B., Seipelt J., DickGudenus R., Muster T. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis. 2010, 1; 201(3), 354–62.
- López-Macías C. Virus-like particle (VLP)-based vaccines for pandemic infl uenza: performance of a VLP vaccine during the 2009 influenza pandemic. Hum Vaccin Immunother. 2012, 8(3), 411–4.
- Draper S. J., Cottingham M. G., Gilbert S. C. Utilizing poxviral vectored vaccines for antibody inductionprogress and prospects. Vaccine 2013, 31, 4223–30. 4. Vemula S. V., Ahi Y. S., Swaim A. M., Katz J. M., Donis R., Sambhara S., Mittal S. K. Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness. PLoS One 2013, 8, 624–96.
Supplementary files
